Yüklüyor......
Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19
There is a need for therapeutic approaches to prevent and mitigate the effects of Coronavirus Disease (2019) (COVID-19). The histone deacetylase (HDAC) inhibitor valproic acid, which has been available for the therapy of epilepsy for many years, is a drug that could be repurposed for patients with s...
Kaydedildi:
| Yayımlandı: | Eur J Pharmacol |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier B.V.
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7923868/ https://ncbi.nlm.nih.gov/pubmed/33667455 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejphar.2021.173988 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|